Impact of SGLT2 Inhibitors on Tumor Development Risk in Type 2 Diabetes: A Retrospective Cohort Study
Yuzhe Wang, Yusen Ding, XiangLong Yan, Jia Yao, Meiling Wang, Zhen Li, Yamei Zhu · 2025
Read Impact of SGLT2 Inhibitors on Tumor Development Risk in Type 2 Diabetes: A Retrospective Cohort Study by Yuzhe Wang, Yusen Ding, XiangLong Yan, Jia Yao, Meiling Wang, Zhen Li, Yamei Zhu (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12717026.txt.
Description
Yuzhe Wang and co-authors ask whether a modern diabetes drug class quietly lowers cancer risk. Their 2025 retrospective study compares 350 patients with type 2 diabetes at one institution: about half took SGLT2 inhibitors, the rest other glucose drugs. Tumor incidence and survival were tracked across several cancer types.
Overall tumor incidence was significantly lower in the inhibitor group, driven mainly by fewer lung and ovarian cancers. The same group showed better blood sugar, lipid, and kidney profiles, and longer progression-free and overall survival. Smoking, drinking, and poor glucose control raised risk as expected. Observational comparisons cannot exclude that healthier patients receive newer drugs, and the authors' design cannot fully answer that. Still, the pattern aligns with a growing literature on metabolic drugs and cancer. The study adds a real-world cohort to a question trials have not yet settled.
Catalog record
| CREATOR | Yuzhe Wang, Yusen Ding, XiangLong Yan, Jia Yao, Meiling Wang, Zhen Li, Yamei Zhu |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |